Biotech Drug Report Generated Sep 12, 2026

GTx-101

GRCE·Grace Therapeutics, Inc.

BEARISH

Drug Impact Rating0/10

Trial Phase: Phase 1 (discontinued)
Time to Market: Not applicable — program discontinued
Why 0/10: GTx-101 has been formally discontinued with a $13.5M impairment taken in Q1 FY2027. There are no scheduled catalysts for this drug — it is a dead program. The stock's value is now entirely driven by GTx-104, not GTx-101.

Actionable Insight ▼ BEARISH

GTx-101 has been formally discontinued and written off. Investors should ignore this asset entirely — Grace Therapeutics' stock is now a pure binary play on the GTx-104 NDA resubmission timeline and FDA outcome. Monitor the company's progress on manufacturing remediation and stability data milestones for GTx-104, not GTx-101.

Price Chart

Loading chart...

Executive Summary

GTx-101 is a topical bioadhesive film-forming polymer spray formulation of bupivacaine that was being developed by Grace Therapeutics (GRCE) for pain associated with postherpetic neuralgia (PHN). The drug completed Phase 1 studies and a PK bridging study that met its primary endpoints. However, in Q1 FY2027 (quarter ending June 30, 2026), Grace Therapeutics formally discontinued GTx-101 (along with GTx-102), recording a $13.5M impairment of IPR&D. The company has pivoted entirely to its lead asset GTx-104 (IV nimodipine for aSAH), which received a CRL from the FDA in April 2026. GTx-101 is effectively a dead program with no remaining catalysts.

How It Works

GTx-101 is a topical (applied to the skin) spray that forms a thin, adhesive film containing the anesthetic bupivacaine. It is designed to deliver the numbing drug locally through the skin to treat pain from postherpetic neuralgia (PHN), the nerve pain that can persist after a shingles infection. The bioadhesive film-forming polymer technology aims to keep the drug in contact with the skin for sustained release, potentially offering a non-invasive alternative to injected bupivacaine.

Trial Status

GTx-101 completed four single-dose Phase 1 studies evaluating PK, safety, dose proportionality, and tolerability. A PK bridging study (NCT05517486) comparing GTx-101 to subcutaneous injectable bupivacaine met all primary outcome measures. However, the program has been formally discontinued — Grace Therapeutics recorded a $13.5M impairment of IPR&D for GTx-101 and GTx-102 in Q1 FY2027 and is no longer developing this asset.

The Two-Sided Case

▲ Bull Case2

The PK bridging study met all primary outcome measures, demonstrating that GTx-101 could deliver bupivacaine systemically via topical application, potentially offering a needle-free alternative for PHN pain management.

The bioadhesive film-forming polymer platform could have been applicable to other drugs, though this is now moot given the discontinuation.

▼ Bear Case4

GTx-101 has been formally discontinued — Grace Therapeutics recorded a $13.5M non-cash impairment of IPR&D for GTx-101 and GTx-102 in Q1 FY2027, confirming the program is dead.

The company has pivoted entirely to GTx-104, which itself faces regulatory uncertainty after receiving an FDA Complete Response Letter in April 2026.

GTx-101 never advanced beyond Phase 1 studies, so its clinical and commercial viability was never established.

The PHN pain market is competitive, with generic lidocaine patches, gabapentinoids, and other topical and systemic therapies already available.

Upcoming Catalysts

None — GTx-101 has been discontinued and written off. All company catalysts now relate to GTx-104 NDA resubmission.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Grace Therapeutics, Inc. 8-K GRCE ·Originating report

Sources · 7

Hover a chip for the title

1 gracetx.com2 gracetx.com3 gracetx.com4 clinicaltrials.gov5 biotechdistilled.substack.com6 briefglance.com7 sec.gov